NFKB1 and hypoxia: Nijboer et al. (2008) found that inhibition of early NF-κB-activity by intraperitoneal administration of the NF-κB inhibitor TAT-NBD at 0/3 h has strong neuroprotection in neonatal hypoxia-ischemia model, whereas inhibition of both early and late NF-κB-activity at 0/6/12 h or only late NF-κB activity at 18/21 h aggravated cerebral damage.